Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab in Japanese Patients with CNV Secondary to AMD (EXTEND-I)
NCT00284089Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2005
- Primary completion
- Mar 2007
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ranibizumab in neovascular age-related macular degeneration (NVAMD) (4 arms), sponsored by Novartis. Primary endpoint: Mean Change From Baseline in the Best Corrected Visual Acuity Score at 6 months. Started Apr 2005; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00284089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00284089.